Your browser doesn't support javascript.
loading
One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates.
Denton, Paul W; Othieno, Florence; Martinez-Torres, Francisco; Zou, Wei; Krisko, John F; Fleming, Elisa; Zein, Sima; Powell, Daniel A; Wahl, Angela; Kwak, Youn Tae; Welch, Brett D; Kay, Michael S; Payne, Deborah A; Gallay, Philippe; Appella, Ettore; Estes, Jacob D; Lu, Min; Garcia, J Victor.
Affiliation
  • Denton PW; Division of Infectious Diseases, Department of Internal Medicine, Center for AIDS Research, University of North Carolina, Chapel Hill, North Carolina 27510, USA.
J Virol ; 85(15): 7582-93, 2011 Aug.
Article in En | MEDLINE | ID: mdl-21593172
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Vagina / Adenine / HIV Infections / Reverse Transcriptase Inhibitors / Disease Models, Animal / Organophosphonates Type of study: Clinical_trials Limits: Animals / Female / Humans Language: En Journal: J Virol Year: 2011 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Vagina / Adenine / HIV Infections / Reverse Transcriptase Inhibitors / Disease Models, Animal / Organophosphonates Type of study: Clinical_trials Limits: Animals / Female / Humans Language: En Journal: J Virol Year: 2011 Type: Article Affiliation country: United States